A reviewer's-eye read on the trajectory problem in malignancy recertification.
Adam Gupilan, LVN — Utilization Management
Cancer is the diagnosis reviewers approve fastest at admission and question hardest at month six.
The reason is trajectory. Most terminal cancers hold function relatively well and then fall steeply near the end. A reviewer has that shape in their head. So when a cancer patient is still on service at the third benefit period with a performance status that has not moved, the record reads as one of two things: a patient who is in the decline phase and whose decline was never charted, or a patient with indolent disease who plateaued. The note has to tell the reviewer which.
Nothing below is about proving the patient has cancer. That was settled in period one. Everything below is about proving the patient is moving.
Skipped: "PPS 50%." Repeated at 50% the following period.
Carries: The same scale with its own history and the interval attached.
"PPS 60% (5/2) → 50% (6/28) → 40% (8/22). Now in bed more than half the day; two months ago was up in a chair for meals."
Why it matters: a level is a snapshot, and every diagnosis has patients who sit at 50% for a year. In cancer specifically, a flat performance status across two periods is the most common reason a recert gets pulled for additional documentation, because it contradicts the expected disease shape. The number itself is not the evidence. The slope is.
The trap with a generous admission score. If PPS was scored high at admission to reflect optimism rather than observation, every later period reads as a smaller drop than actually occurred. From the review side an inflated baseline is invisible — I see a shallow line, not a mis-anchored one.
When the slope really is flat. Sometimes it is, and the honest note is stronger than a manufactured decline: state it, then carry the period on a different axis — symptom escalation, procedural interval, transfusion dependence, weight. A flat PPS with three other axes moving is a defensible recert. A flat PPS with nothing else is not.
Skipped: "Patient declined further chemotherapy." Copied forward, verbatim, into every subsequent recert.
Carries: Stating it once, then charting what happened in the absence of treatment.
"Off all disease-directed therapy since 3/14. Since that date: two new sites of bone pain (right hip 6/2, lumbar 7/19), MEDD 30 → 90 mg, ambulation lost."
Why it matters: refusal or failure of curative treatment establishes eligibility at entry. It says nothing about the current period. When it is the most prominent sentence in a period-four note, the reviewer reads a record with no current-period argument in it — and copy-forward language is conspicuous, because it is usually the only sentence in the note with no dates in it.
Skipped: "No recent imaging." "Restaging not pursued, consistent with goals of care." Then nothing.
Carries: Progression evidenced by the body rather than the scanner.
"New left-sided weakness 7/30, new headache, dexamethasone started — clinically consistent with CNS progression. Not imaged; consistent with goals of care."
"Paracentesis interval shortened: 6 weeks (May) → 3 weeks (July) → 10 days (August). Volume per tap increased 3.5 L → 5 L."
Why it matters: reviewers do not expect a hospice patient to be restaged, and asking for imaging would be asking the agency to work against the plan of care. But "not imaged" is not an argument — it is the removal of one. The substitute is clinical progression: new anatomic sites, new neurologic findings, new obstructive symptoms, new or recurring effusion or ascites.
Procedural intervals are the most underused item in the cancer chart. Time between thoracenteses, paracenteses, or transfusions is a hard number, already recorded, that shortens as disease advances. A shrinking interval is progression stated arithmetically. Almost nobody puts it in the narrative.
Skipped: "Weight loss noted." "Poor appetite."
Carries: Serial weights with the interval, plus what did not stop it.
"142 → 128 lbs over 11 weeks (9.9%). No edema. Megestrol trialed 6/10, discontinued 7/22 for lack of effect. Intake 25% of meals, from 60% in May."
Why it matters: this is where cancer differs from heart failure. In CHF a stable weight can mean volume masking loss, so the number needs a fluid-status companion to be readable at all. In most advanced cancer, absent ascites or anasarca, weight loss is real tissue loss and reviewers take it at face value. It is one of the few places in a hospice chart where the plain number is sufficient — as long as it is serial and dated.
Decline that continued despite intervention is the strongest phrasing available. An appetite stimulant that failed is better evidence than one that was never tried.
Skipped: "Pain controlled on current regimen." "Pain 6/10."
Carries: Dose trend anchored to something that rules out tolerance.
"MEDD 45 → 120 mg over six weeks. Escalation accompanies a new pain site (right proximal femur, onset 7/28) and addition of gabapentin for new neuropathic quality — not dose tolerance at a stable site."
Why it matters: opioid escalation is a clean, timestamped, quantitative signal, and it is also the one a careful reviewer discounts most readily, because tolerance produces the same curve as progression. The distinguishing information is almost always already in the chart: a new site, a new pain character, a new adjuvant class, a palliative radiation referral, or a simultaneous drop in function. Escalation plus any one of those reads as disease. Escalation alone reads as pharmacology.
Skipped: The primary site, with no comment on tempo.
Carries: An explicit statement of why this course is aggressive.
"Metastatic castration-resistant prostate cancer with visceral (hepatic) metastases and transfusion-dependent anemia — transfusion interval 5 weeks → 12 days since June. Course is not the indolent bone-only pattern."
Why it matters: some malignancies routinely support long survival — prostate, low-grade lymphoma, some hormone-receptor-positive breast, some renal. At an extended length of stay, a reviewer looking at one of those histologies starts from skepticism, and a note that only names the diagnosis confirms it. A note that names the diagnosis and distinguishes this patient's course from the indolent version answers the objection before it is raised.
Skipped: Silence, because "no hospitalization" feels like the absence of information.
Carries: Events during the period, and events actively prevented.
"Hypercalcemia of malignancy 8/4, managed at home with hydration per goals; ED transfer declined. Third episode since June. Two units PRBC 7/19 and 8/16 for symptomatic anemia."
Why it matters: an avoided admission is invisible unless it is charted, and it is simultaneously evidence of decline and evidence the benefit is working. Silence in this section reads as stability, which is the one conclusion the record cannot afford.
A cancer recert containing these five, each with dates, clears review in most cases:
The rest of the note serves the patient. These five serve the claim.
In heart failure the reviewer is asking how sick. In cancer the reviewer is asking how fast.
A note that answers the first question about a cancer patient has answered a question nobody asked.
Written from the utilization management side. No product attached to this — take what's useful.
This series is written one diagnosis at a time, and the useful ones to write next are the ones people are actually losing. If there's a recertification or authorization that keeps coming back on your charts and it isn't covered above, name it and I'll write it up.
No cost, no pitch attached, and nothing patient-specific — the diagnosis and the setting is all I need. If it's a common one, it goes into the series so everyone gets it.
Name a diagnosis →I do utilization review on the payer side, so this is written from the chair the note actually lands in. I also build software for this, at getclinicalflow.com — but nothing above depends on it and there's no obligation attached to asking.
Adam Gupilan, LVN — utilization management. I review the prior authorizations and recertifications that providers submit, which is where everything above comes from.
Nothing here is attached to a product. If it's useful in your charts, use it. More at the full series, or getclinicalflow.com.
Written from the reviewer's side and offered as general documentation guidance. It is not clinical, legal, or billing advice, and it does not reproduce any proprietary criteria text. Eligibility determinations are made by the certifying physician and the reviewing plan.